


7th Annual MarketsandMarkets Biomarker & Companion Diagnostics Conference – Innovations in Targeted Therapies

PUNE, MH , INDIA, May 18, 2022

/EINPresswire.com/ -- The pandemic has accelerated investments into the Biomarker Industry & multiplied the subsequent growth and development of companion diagnostics by leaps & bounds. The evolution of targeted therapies has progressively turned the heads of the healthcare ecosystem thus also growing the need for companion diagnostics.



A large number of medicines now require a biomarker-based patient selection system. Companion Diagnostics are herein being used to detect the presence of certain biomarkers which allow for accurate filtering of patients as responders and non-responders. These CDx tests are linked to therapeutic drugs to increase the efficiency and success of treatment and therapy.

As we move forward & novel technologies emerge, the applications for this field will further enlarge.

The 7TH ANNUAL MARKETSandMARKETS BIOMARKER & COMPANION DIAGNOSTICS CONFERENCE scheduled for the 16th & 17th JUNE in SAN DIEGO aims to gather leading scientists, researchers & industry leaders to showcase important case studies & keynote presentations on the latest trends post pandemic as well as discuss the future road map with the advent of Next Gen Sequencing & Big Data and their effects on Digital Biomarkers and CDx.

KEY HIGHLIGHTS & EXPECTED TAKEAWAYS:

- Commercialization of Companion Diagnostics (CDx)
- Proteomics and Genomics based Biomarkers
- Biomarker Drug Discovery and Assay Development
- Multiplex Companion Diagnostics and Regulatory Guidelines
- Design of clinical trials in Companion Diagnostics (CDx)
- Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data
- Clinical Applications of Biomarkers in Immuno-Oncology, Neurology, and Inflammatory Diseases

A GLIMPSE OF OUR ESTEEMED SPEAKER PANEL:

- John Rossi, SVP, Head, Translational Medicine, CERO THERAPEUTICS
- Andrea Giuliani, Director, Business Development, Oncology & Precision Diagnostics, QIAGEN
- Medieh Saffari, Biomarker Clinical Assay Lead, Manager, PFIZER
- Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD SERONO
- Mike Baratta, Scientific Director, Clinical Biomarker Development & Innovation, TAKEDA
- Christos Patriotis, Program Director, Breast & GYN Cancers, NCI, NIH
- Bartha Das, Medical Director, Oncology CDx and Biomarkers, AMGEN
- Israel Katz, Medical Director, Clinical Development, VIRACTA THERAPEUTICS
- Paul Kassner, SVP, Quantitative & Computational Biology, RAPT THERAPEUTICS
- Brancie Barron, VP Innovation & Partnerships, CARDEABIO
- Roy Baynes, SVP, & Head Global Clinical Development, Chief Medical Officer, MERCK RESEARCH LABORATORIES

LEARN MORE ABOUT THE SPEAKERS & PRESENTATIONS - [EXPLORE THE ENTIRE 2-DAY AGENDA HERE!](#)

[REGISTER FOR THE CONFERENCE!](#)

Ayush Kanitkar
MarketsandMarkets
+91 89759 85061
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/572983324>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.